Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

BACKGROUND: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non–small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline “window-of-opportunity” study. METHODS: Patients received 25 mg of temsirolimus administered intravenously...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Thorac Oncol
Glavni autori: Reungwetwattana, Thanyanan, Molina, Julian R., Mandrekar, Sumithra J., Allen-Ziegler, Katie, Rowland, Kendrith M., Reuter, Nicholas F., Luyun, Ronnie F., Dy, Grace K., Marks, Randolph S., Schild, Steven E., Jett, James R., Adjei, Alex A.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5740874/
https://ncbi.nlm.nih.gov/pubmed/22722792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31824de0d6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items